Middle East and North African leaders seek solutions to diabetes threat
- Details
- Category: Novo Nordisk
The Middle East and Northern Africa (MENA) region is facing one of the greatest healthcare challenges of our time: the diabetes pandemic. It is estimated that 26.6 million people in the region have diabetes and this number is set to double to 51.7 million by 2030.
LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients
- Details
- Category: Boehringer Ingelheim
New data to be presented show that afatinib (BIBW 2992) leads to a significant four-fold extension (4.4 months vs. 1 month for placebo) in progression-free survival - the time before a tumour starts to grow again - for lung cancer patients most likely to have an epidermal growth factor receptor (EGFR) mutation.
GSK to acquire Nanjing MeiRui Pharmaceuticals in China
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd (MeiRui) for a cash consideration of approximately $70 million.
Three Innovative Ideas Receive $10,000 Prizes in Patients | Choices | Empowerment Competition
- Details
- Category: Amgen
The Amgen Foundation and Ashoka's Changemakers today announced three winners for the Patients | Choices | Empowerment competition. Each winner will receive a $10,000 cash prize and was selected by the public for their innovative solutions that empower and elevate patients' voices to improve health outcomes.
Merck KGaA Donation Program Supports Schistosomiasis Control in Africa
- Details
- Category: Merck Group
Merck KGaA is supporting the World Health Organization (WHO) in the fight against the neglected tropical disease schistosomiasis, which is the most common tropical disease in Africa after malaria and a major public health problem. Around 200 million people in Africa suffer from schistosomiasis, 200,000 of whom die each year.
Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma
- Details
- Category: Bristol-Myers Squibb
Abbott (NYSE: ABT) and Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone.
Novo Nordisk presents positive clinical data on two investigational compounds within bleeding disorders
- Details
- Category: Novo Nordisk
Novo Nordisk presented data from a phase 2 trial evaluating the safety, pharmacokinetics and efficacy of a recombinant factor VIIa (rFVIIa) analogue, designed to have a faster action profile than NovoSeven® (rFVIIa) in haemophilia patients with inhibitors (antibody formation against factor preparations).
More Pharma News ...
- Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib
- Public believe China and India set to become World leaders for innovation
- Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80%
- Amgen's Nplate(R) Maintains Platelet Counts for More Than Five Years in Adults with Chronic ITP
- Commitment of Novartis in advancing treatments for patients with cancer and rare diseases
- Genzyme Completes Sale of Genetic Testing Business to LabCorp
- Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration